PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24201549-4	2014	RESULTS: The combination of NAD and RT-CAD significantly decreased tumour [C]choline uptake (SUV60,ave, SUV60,max, TMR60,max or Kimod-pat) and prostate-specific antigen (PSA) levels (analysis of variance, P<0.001 for all variables).	nadide	28-31	kallikrein related peptidase 3	Homo sapiens	143-174	
24201549-6	2014	A wide range of reduction in tumour SUV60,ave (38-83.7%) and SUV60,max (22.2-85.3%) was seen with combined NAD and RT-CAD despite patients universally achieving PSA suppression (narrow range of 93.5-99.7%).	nadide	107-110	kallikrein related peptidase 3	Homo sapiens	161-164	
24201549-8	2014	The reduction in tumour SUV60,ave after NAD was associated with PSA reduction (r=0.7, P=0.04).	nadide	40-43	kallikrein related peptidase 3	Homo sapiens	64-67	
24201549-11	2014	A differential reduction in [C]choline uptake despite a global reduction in PSA following NAD and RT-CAD could provide prognostic information and warrants further evaluation as an imaging biomarker in this setting.	nadide	90-93	kallikrein related peptidase 3	Homo sapiens	76-79